The subject of the present invention is a method for detecting active, remyelinating lesions in patients diagnosed with multiple sclerosis through the determination of changes in the levels of interleukin-33 in peripheral blood and cerebrospinal fluid, which constitutes a novel marker of endogenous repair processes facilitating the monitoring of the differentiation of oligodendrocyte precursor differentiation in patients.

Patent was granted in Poland and Nencki Institute is the sole applicant.

For more information contact Technology Transfer Office.